Injectafer
(Ferric Carboxymaltose)ApprovedSmall molecule
Ferric carboxymaltose is used to treat iron deficiency anemia, a condition where your body doesn't have enough iron to make healthy red blood cells, which can cause fatigue and weakness.[2] Injectafer is currently approved and in use across 22 indications[4].[1]
Injectafer is one of 486 small molecule programs targeting Heart Failure. It is currently in Approved.
22
Indications
108
Total Trials
9
Active Trials
485
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
9
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 21 indications
Competition
Competitive Landscape
282 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Ninlaro
TakedaPhase 3
Venclexta
AbbViePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Injectafer
AAmerican Regent, Inc.
Approved
Neulasta
AmgenPhase 3
Elranatamab
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Cytosar
TevaPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Iron deficiency anemia13 trials
The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department
Not yet recruiting·—·Phase 4·NCT07414199·150 enrolled
Show 10 more trials
Heart Failure12 trials
Show 9 more trials
Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction
Unknown status·—··NCT04974021·106 enrolled
Anemia9 trials
Show 6 more trials
Impact of Intravenous Iron Treatment of Preoperative Anemia in Patients With LEAD (IRONPAD)
Unknown status·—·Phase 4·NCT04083755·240 enrolled
Iron-deficiency6 trials
Iron Supplementation in TAVI and SAVR Patients With Iron Deficiency
Unknown status·—·Phase 4·NCT04786769·2,500 enrolled
Chronic Kidney Disease5 trials
Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)
Completed·—·Phase 4·NCT02232906·30 enrolled
47 more indications
Intravenous4 trials
CAR3 trials
Restless Legs Syndrome3 trials
Hypophosphatemia3 trials
Inflammatory Bowel Disease3 trials
Hemoglobin2 trials
Total Knee Arthroplasty2 trials
Hip Fracture2 trials
Intraoperative2 trials
Cardiac Surgery2 trials
Pulmonary Hypertension1 trial
Acute Coronary Syndrome1 trial
Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome
Recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT07476859·538 enrolled
Pediatric1 trial
Safety and Efficacy1 trial
Treatment1 trial
Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia
Unknown status·—·Phase 4·NCT02243735·198 enrolled
Chronic Obstructive Pulmonary Disease1 trial
Gastrointestinal Stromal Tumor1 trial
Homeostasis1 trial
Hemodialysis1 trial
Do Iron And Vitamin B12 Injections Given Together, Improve Hemoglobin In Patients On Hemodialysis?
Unknown status·—·Phase 4·NCT04627181·100 enrolled
Kidney Transplant1 trial
Pediatric Patients1 trial
Efficacy1 trial
An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function
Completed·—·N/A·NCT05309499·298 enrolled
Complication1 trial
Critically Ill1 trial
Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill
Withdrawn·—·Phase 1·NCT02009943
Multiple Myeloma1 trial
Type 2 Diabetes Mellitus1 trial
Breast Cancer1 trial
Regulatory
FDA Approval Timeline[5]
Sep 5, 2014
AURYXIA
NDA NDA205874
Apr 28, 2021
INJECTAFER
NDA NDA203565
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Injectafer drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ferric Carboxymaltose. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAmerican Regent, Inc.